{
  "Country": "FR",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Progression-free survival, objective response rate, overall survival, duration of response, disease control rate, delay until response, quality of life, safety profile."
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Ramucirumab + Docetaxel",
      "Outcomes": "Progression-free survival, objective response rate, overall survival, duration of response, disease control rate, delay until response, quality of life, safety profile."
    }
  ],
  "SourceType": "hta_submission"
}